A new study published by British Medical Journal has shown the bladder cancer risk associated with Actos is much higher than previously anticipated.
When major concerns about the drug’s relation to bladder cancer arose last June, scientists estimated that Actos increased patients’ risks of developing the illness by 40%. The new study places that figure at closer to 83%.
Actos was marketed as a safer alternative to Avandia, but the study concluded that the increased bladder cancer risk was Actos-specific. The bladder cancer rate increases even more for people who take the drug for longer than two years.
If you have taken Actos and have since been diagnosed with bladder cancer, contact the Actos lawsuit attorneys of Williams Kherkher at 800-641-9810.